Glycogen storage disease type II epidemiology and demographics: Difference between revisions
No edit summary |
|||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Glycogen storage disease type II}} | {{Glycogen storage disease type II}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}}{{Anmol}} | ||
==Overview== | ==Overview== |
Revision as of 16:16, 11 January 2018
Glycogen storage disease type II Microchapters |
Differentiating Glycogen storage disease type II from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Glycogen storage disease type II epidemiology and demographics On the Web |
American Roentgen Ray Society Images of Glycogen storage disease type II epidemiology and demographics |
FDA on Glycogen storage disease type II epidemiology and demographics |
CDC on Glycogen storage disease type II epidemiology and demographics |
Glycogen storage disease type II epidemiology and demographics in the news |
Blogs on Glycogen storage disease type II epidemiology and demographics |
Directions to Hospitals Treating Glycogen storage disease type II |
Risk calculators and risk factors for Glycogen storage disease type II epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anmol Pitliya, M.B.B.S. M.D.[2]
Overview
Epidemiology and Demographics
Incidence
- The incidence of glycogen storage disease type 2 (GSD type 2) is approximately 11.5 per 100,000 individuals in the state of Illinois, United States.[1]
- The predicted incidence of glycogen storage disease type 2 is approximately 2.5 per 100,000 individuals in Netherlands. This incidence in divided into 0.7 per 100,000 individuals for infantile GSD type 2 and 1.8 per 100,000 individuals for adult GSD type 2.[2]
Prevalence
- The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
- In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
- The prevalence of [disease/malignancy] is estimated to be [number] cases annually.
Case-fatality rate/Mortality rate
- In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
- The case-fatality rate/mortality rate of [disease name] is approximately [number range].
Age
- Patients of all age groups may develop [disease name].
- The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
- [Disease name] commonly affects individuals younger than/older than [number of years] years of age.
- [Chronic disease name] is usually first diagnosed among [age group].
- [Acute disease name] commonly affects [age group].
Race
- There is no racial predilection to [disease name].
- [Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
Gender
- [Disease name] affects men and women equally.
- [Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.
Region
- The majority of [disease name] cases are reported in [geographical region].
- [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
Developed Countries
Developing Countries
References
- ↑ Burton BK, Charrow J, Hoganson GE, Waggoner D, Tinkle B, Braddock SR; et al. (2017). "Newborn Screening for Lysosomal Storage Disorders in Illinois: The Initial 15-Month Experience". J Pediatr. 190: 130–135. doi:10.1016/j.jpeds.2017.06.048. PMID 28728811.
- ↑ Ausems MG, Verbiest J, Hermans MP, Kroos MA, Beemer FA, Wokke JH; et al. (1999). "Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling". Eur J Hum Genet. 7 (6): 713–6. doi:10.1038/sj.ejhg.5200367. PMID 10482961.